Optos Unveils Silverstone RGB, Setting a New Standard for Retinal Imaging Technology

The only device combining 200° single shot true-to-life color imaging with advanced swept-source OCT.

Dunfermline, UK — 15 October, 2025 — Optos, the global leader in ultra-widefield (UWF™) retinal imaging, today announced the launch of Silverstone RGB, the most advanced product in the company's history. Building on its flagship Silverstone platform, the new system delivers an unmatched suite of nine imaging modalities in a single device, establishing a new benchmark in retinal imaging.

"Silverstone RGB represents a transformative step forward for eye care professionals," said Masayuki Numako, Director & Executive Vice President Head of Healthcare Business Division, Nikon Europe B.V. "By combining 200° single-shot ultra-widefield optomap^® technology, true-to-life color accuracy, and advanced swept-source OCT, clinicians can evaluate retinal pathology with unparalleled confidence, and efficiency."

Silverstone RGB offers the broadest spectrum of retinal imaging capabilities available, enabling clinicians to capture, visualize, and analyze pathology across every layer of the retina. The nine modalities include optomap color RGB for true-to-life retinal color imaging, optomap color RG as the proven clinical standard, supported by more than 3,000 peer-reviewed studies, optomap fluorescein angiography (FA) for vascular evaluation and disease detection, optomap indocyanine green angiography (ICG) for enhanced choroidal and vascular imaging, optomap Sensory Red-Free for highlighting nerve fiber and vascular structures, optomap Choroidal Imaging for deep tissue visualization, optomap Green Autofluorescence (AF) for identifying RPE changes and metabolic activity, optomap Blue Autofluorescence (AF) for visualizing subtle retinal pathology, and Swept-Source OCT for high-resolution, navigable imaging anywhere in the retina

Silverstone RGB will debut at the American Academy of Ophthalmology (AAO) in Orlando, Florida beginning 18 October 2025 and will be available immediately in direct markets

For more information about Optos, visit www.optos.com

About Optos

For more than 30 years, Optos has been the exclusive provider of 200-degree single-shot ultra-widefield retinal imaging systems to eye care professionals worldwide. With over 27,000 devices in use and supported by more than 3,000 clinical papers, Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. Optos continues to lead the way in retinal imaging technology, setting the standard for excellence and innovation in eye care.

OPTOS Media Contact:
Cassy Dump
Shine Communications for Optos
Cassy@heyshine.com
(619) 971-1887